CHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit

Deep News03-26

CHINARES PHARMA (03320) saw its shares rise more than 6% during morning trading. At the time of writing, the stock was up 6.24%, trading at HK$5.28, with a turnover of HK$192 million.

The company released its annual results, reporting group revenue of RMB 269.574 billion, a year-on-year increase of 4.62%. Profit attributable to shareholders reached RMB 4.045 billion, up 20.73% compared to the previous year. Earnings per share were RMB 0.64. A final dividend of RMB 0.122 per share was declared, representing an increase of approximately 135% year-on-year.

At the business level, the pharmaceutical segment recorded revenue of RMB 51.039 billion, growing 10.2% year-on-year, with significant growth in traditional Chinese medicine, biologics, nutritional supplements, and other segments. The pharmaceutical distribution business generated revenue of RMB 220.08 billion, up 3.2% year-on-year. Revenue from pharmaceutical retail operations reached RMB 12.21 billion, increasing 20.8% year-on-year, driven by strong growth in the Direct-to-Patient (DTP) business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179671796?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179671796","market":"sh","top_or_hot":-1,"title":"CHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit","media":"Deep News","content":"<p>CHINARES PHARMA (03320) saw its shares rise more than 6% during morning trading. At the time of writing, the stock was up 6.24%, trading at HK$5.28, with a turnover of HK$192 million.</p>\n<p>The company released its annual results, reporting group revenue of RMB 269.574 billion, a year-on-year increase of 4.62%. Profit attributable to shareholders reached RMB 4.045 billion, up 20.73% compared to the previous year. Earnings per share were RMB 0.64. A final dividend of RMB 0.122 per share was declared, representing an increase of approximately 135% year-on-year.</p>\n<p>At the business level, the pharmaceutical segment recorded revenue of RMB 51.039 billion, growing 10.2% year-on-year, with significant growth in traditional Chinese medicine, biologics, nutritional supplements, and other segments. The pharmaceutical distribution business generated revenue of RMB 220.08 billion, up 3.2% year-on-year. Revenue from pharmaceutical retail operations reached RMB 12.21 billion, increasing 20.8% year-on-year, driven by strong growth in the Direct-to-Patient (DTP) business.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-03-26 10:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA (03320) saw its shares rise more than 6% during morning trading. At the time of writing, the stock was up 6.24%, trading at HK$5.28, with a turnover of HK$192 million.</p>\n<p>The company released its annual results, reporting group revenue of RMB 269.574 billion, a year-on-year increase of 4.62%. Profit attributable to shareholders reached RMB 4.045 billion, up 20.73% compared to the previous year. Earnings per share were RMB 0.64. A final dividend of RMB 0.122 per share was declared, representing an increase of approximately 135% year-on-year.</p>\n<p>At the business level, the pharmaceutical segment recorded revenue of RMB 51.039 billion, growing 10.2% year-on-year, with significant growth in traditional Chinese medicine, biologics, nutritional supplements, and other segments. The pharmaceutical distribution business generated revenue of RMB 220.08 billion, up 3.2% year-on-year. Revenue from pharmaceutical retail operations reached RMB 12.21 billion, increasing 20.8% year-on-year, driven by strong growth in the Direct-to-Patient (DTP) business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1179671796","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179671796","pubTimestamp":1774491767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CHINARES PHARMA (03320) saw its shares rise more than 6% during morning trading. At the time of writing, the stock was up 6.24%, trading at HK$5.28, with a turnover of HK$192 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药","BK1570":"华润系","BK1191":"制药"},"translate_title":"年度净利润增长20.73%后，CHINARES PHARMA股价早盘飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"CHINARES PHARMA (03320) saw its shares rise more than 6% during morning trading. At the time of writing, the stock was up 6.24%, trading at HK$5.28, with a turnover of HK$192 million.\nThe company released its annual results, reporting group revenue of RMB 269.574 billion, a year-on-year increase of 4.62%. Profit attributable to shareholders reached RMB 4.045 billion, up 20.73% compared to the previous year. Earnings per share were RMB 0.64. A final dividend of RMB 0.122 per share was declared, representing an increase of approximately 135% year-on-year.\nAt the business level, the pharmaceutical segment recorded revenue of RMB 51.039 billion, growing 10.2% year-on-year, with significant growth in traditional Chinese medicine, biologics, nutritional supplements, and other segments. The pharmaceutical distribution business generated revenue of RMB 220.08 billion, up 3.2% year-on-year. Revenue from pharmaceutical retail operations reached RMB 12.21 billion, increasing 20.8% year-on-year, driven by strong growth in the Direct-to-Patient (DTP) business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179671796","isCrawlerRequest":true}